warfarin

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

AAS vs Warfarin in Low Risk TAVR

We are still discussing the adequate antithrombotic scheme after transcatheter aortic valve replacement (TAVR). Additionally, we are treating a much wider array of patients ranging from low risk to inoperable.&nbsp; And there is yet one more important point: hypo-attenuated leaflet thickening diagnosed by CT. We are still unaware of the impact they have on device<a href="https://solaci.org/en/2021/03/15/aas-vs-warfarin-in-low-risk-tavr/" title="Read more" >...</a>

AHA 2020 | RIVER: Rivaroxaban como alternativa a la warfarina en pacientes con fibrilación auricular y protesis mitral biológica

AHA 2020 | RIVER: Rivaroxaban as Alternative to Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Mitral Valve

Rivaroxaban seems to be a reasonable alternative to warfarin in patients with atrial fibrillation and bioprosthetic mitral valve. These results arise from the RIVER Study presented at the American Heart Association (AHA) 2020 Congress and simultaneously published in the New England Journal of Medicine (NEJM). After 5 years of follow-up, rivaroxaban reached the non-inferiority criterion<a href="https://solaci.org/en/2020/11/20/aha-2020-river-rivaroxaban-as-alternative-to-warfarin-in-patients-with-atrial-fibrillation-and-bioprosthetic-mitral-valve/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS

Courtesy of SBHCI. The safety and efficacy of antithrombotic and antiplatelet treatments in patients with atrial fibrillation admitted with acute coronary syndrome (who receive medical treatment or angioplasty) may vary from that in patients undergoing elective treatment. At 14&nbsp;days from elective angioplasty or hospitalization due to acute coronary syndrome, patients were randomized in a 2×2<a href="https://solaci.org/en/2019/09/30/tct-2019-augustus-acs-a-2x2-factorial-randomized-trial-of-apixaban-vs-warfarin-and-aspirin-vs-placebo-in-patients-with-atrial-fibrillation-and-an-acute-coronary-syndrome/" title="Read more" >...</a>

Valve Thrombosis After TAVR: Larger-Diameter Valves and No Warfarin as Predictors

There are limited data on the incidence, clinical implications, and predisposing factors of valve thrombosis in patients who underwent transcatheter aortic valve replacement (TAVR). This study aimed at determining such information through multislice computed tomography (CT). &nbsp; This trial included 460&nbsp;consecutive patients who underwent TAVR with a balloon-expandable Edwards Sapien XT or Sapien&nbsp;3 (Edwards Lifesciences,<a href="https://solaci.org/en/2016/11/13/valve-thrombosis-after-tavr/" title="Read more" >...</a>

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

Cost-Effectiveness of Left Atrial Appendage Closure and the New Anticoagulants vs. Warfarin in Atrial Fibrillation

Original Title: Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF Warfarin vs. NOACs vs. LAA Closure. Reference: Vivek Y. Reddy et al. J Am Coll Cardiol. 2015;66(24):2728-2739. Left atrial appendage closure and the new anticoagulants (NOACs) have emerged as safe and effective alternatives to warfarin for stroke in patients with non-valvular atrial fibrillation. This analysis<a href="https://solaci.org/en/2015/12/23/cost-effectiveness-of-left-atrial-appendage-closure-and-the-new-anticoagulants-vs-warfarin-in-atrial-fibrillation/" title="Read more" >...</a>

Bleeding Events after Left Atrial Appendage Closure vs. Long Term Warfarin

Original Title: Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. Reference: Matthew J. Price et al. J Am Coll Cardiol Intv. 2015. Online before print. The aim of this trial was to compare the relative risk of major bleeding after left atrial appendage closure<a href="https://solaci.org/en/2015/12/15/bleeding-events-after-left-atrial-appendage-closure-vs-long-term-warfarin/" title="Read more" >...</a>

COAG Trial: Dose of warfarin and Pharmacogenetics

Observational studies identified two genes that influence the dose of warfarin (CYP2C9 and VKORC1). The clinical utility of dose adjustment by genetics has been tested only in small studies with conflicting results. In this multicenter, double-blind randomized 1015 patients comparing strategy initiation of therapy using only clinical information versus using patient&#8217;s genotype. The primary endpoint<a href="https://solaci.org/en/2015/06/24/congress-item-7595/" title="Read more" >...</a>

ENGAGE AF-TIMI 48: Endoxaban versus warfarin in atrial fibrillation

The endoxaban is an oral direct inhibitor of factor Xa with a rapid onset of action and a half-life of 8-10 hours. Endoxaban efficacy and safety for long-term versus warfarinin patients with atrial fibrillation was not studied. This was a randomized, double-blind study that compares two different regimes of endoxaban with warfarin in 21105 patients<a href="https://solaci.org/en/2015/06/24/congress-item-7567/" title="Read more" >...</a>

EU-PACT: Warfarin dose guided by genotype

Anticoagulation level in response to a fixed dose of warfarin is difficult to predict at the start of therapy. The CYP2C9 gene polymorphism (involved in the metabolism of warfarin) and VKORC1 (involved in the vitamin K cycle) with the age and the body surface are responsible for about 50% of the individual variability in dose.<a href="https://solaci.org/en/2015/06/24/congress-item-7574/" title="Read more" >...</a>

PREVAIL: LAA occlusion versus anticoagulation with warfarin to prevent stroke in patients with non-valvular atrial fibrillation.

An hour before the presentation of the PREVAIL study, the ACC announced the cancellation of the release of the study results. Due to an error in the email system, results of the study were reported a few hours before his presentation. The ACC in an unprecedented decision cancelled the presentation of the study as well<a href="https://solaci.org/en/2015/06/24/congress-item-6699/" title="Read more" >...</a>

Top